Saturday, 08 August 2020

CEVEC signs deal with Yuhan in South Korea

24 December 2012 | News | By BioSpectrum Bureau

License agreement - Yuhan to use CEVEC CAP-T technology

License agreement - Yuhan to use CEVEC CAP-T technology

Singapore: CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation, a leading manufacturer of pharmaceutical products based in Seoul, South Korea, announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins.

CAP-T CAP cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior protein yields in a shorter time frame than traditional methods.

"With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We're very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I'm convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases," stated Dr Wolfgang Kintzel, CEO, CEVEC.

Dr Jong-Gyun Kim, head, bio-innovation unit, Yuhan Research Institute, said that, "After evaluating CAP and CAP-T we are excited about the potential of CEVEC's CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it's authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules"

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls